Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging

NACompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 16, 2018

Primary Completion Date

June 6, 2023

Study Completion Date

December 20, 2023

Conditions
Type II Diabetes
Interventions
DRUG

GLP-1 agonists

Liraglutide: 6 mg/ml Semaglutide: 1.34 mg/ml Dulaglutide: de 0.75 mg ou 1.5 mg

PROCEDURE

Cardiac MRI

T3 myocardial MRI (total acquisition time : 1h) performed before initiation of treatment and measuring the concentration of intramyocardial triglycerides (\[TG\] by NMR spectroscopy, parameters of cardiac morphology (myocardial mass, (epicardial fat surface, pericardial fat surface), function (LVEF, SV, TDV, PFR, TPFR) and tissue parameters (extracellular volume, left myocardial fibrosis volume).

OTHER

Follow up by phone

at 2 and 4 mois

Trial Locations (1)

21000

Chu Dijon Bourgogne, Dijon

All Listed Sponsors
lead

Centre Hospitalier Universitaire Dijon

OTHER

NCT03498001 - Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging | Biotech Hunter | Biotech Hunter